

AMENDMENT TO THE CLAIMS

1 - 125. (CANCELED).

126. (PREVIOUSLY PRESENTED) A pharmaceutical tablet comprising substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate and a pharmaceutically acceptable carrier or diluents.

127. (CANCELED)

128. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum comprising at least one peak with chemical shift of about 179.5 ppm.

129. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 128, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 178.6 ppm.

130. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 129, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 58.0 ppm.

131. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 130, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 17.2 ppm.

132. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 131, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 10.1 ppm.

133. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 132, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 9.8 ppm.
134. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 133, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 9.3 ppm.
135. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 134, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 7.9 ppm.
136. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 135, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 6.6 ppm.
137. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 82% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.
138. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 84% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.
139. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol

solvate comprises 86% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

140. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 88% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

141. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 90% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

142. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 94% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

143. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 96% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

144. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 98% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.

145. (PREVIOUSLY PRESENTED) The pharmaceutical tablet of claim 126, wherein said substantially pure crystalline azithromycin monohydrate hemi-ethanol solvate comprises 99% or more by weight of crystalline azithromycin monohydrate hemi-ethanol solvate.